Novartis, Cota Healthcare bring data analytics to breast cancer treatment

Novartis Pharmaceuticals Corp. signed a multiyear agreement to use Cota Healthcare's precision medicine platform.

The collaboration aims to accelerate the clinical development of new breast cancer therapies. Novartis research teams will use Cota's analysis and visualization tools — including the Cota Nodal Address platform, a digital classification system that stratifies patients based on relevant personal and clinical factors — to identify optimal treatments for patients and predict outcomes.

"Analyzing this data using CNAs is a critical factor in enabling healthcare companies to develop and target therapies that increase outcomes and lower the total cost of care," said Andrew Pecora, MD, founder and executive chairman of Cota. "We're excited about helping Novartis get deep insight into how patients are getting treatment in practice."

More articles on population health:
Genomics company taps former Microsoft researcher as chief data scientist
Bigger than opioids: 5 things to know about 'deaths of despair' afflicting middle-aged whites
American Heart Association launches data sharing platform

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 
 

Top 40 Articles from the Past 6 Months